Segments - Primary Care POC Diagnostics Market by Products (Glucose Testing, Hb1Ac Testing, Coagulation, Fertility, Infectious Diseases, Cardiac Markers, Thyroid Stimulating Hormone, Hematology, Primary Care Systems, Decentralized Clinical Chemistry, Feces, Lipid Testing, Cancer Marker, Blood Gas/Electrolytes, Ambulatory Chemistry, Drug Abuse Testing, and Urinalysis), End-users (Pharmacy & Retail Clinics, Physician Office, Urgent Care Clinics, and Non-practice Clinics), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028
The global primary care POC diagnostics market size was valued at USD 7.38 billion in 2020 and is expected to register a substantial CAGR during the forecast period, 2021-2028. The market growth is attributed to the swift evolution of the point to care testing (POCT) and growing adoption of the diagnostics for various medical applications from patients. The POCT has immense potential in terms of growth, be it primary or secondary care settings, which helps in the significant growth of the primary care POC diagnostics market.
The primary care POC diagnostics is widely adopted to identify and measure the level and strength of various key components and elements to ensure a healthy body and also to observe and monitor for the treatment required of a disease. This diagnostic report is further used for evaluation and a summary of the report is normally being sent to the concerned clinic, which devises a proper treatment for the patient. Various kinds of POCTs were developed to study different anatomies of the body, be it internal or external. For instance, after the introduction of urine test strips, wherein the patient’s urine strip is studied on a separate apparatus for the detection of drugs or toxic, portable ultrasonography offers a better result showing accurate readings in limited time. Now, this method is considered to be a simple technology and is also found its usage in other liquid test evaluations such as blood sample testing. One key aspect of POCTs is that it can offer a wide range of tests immediately, which provides certain conveniences to patients. This helps to improve the treatment of patients since the physician and healthcare team can function more efficiently once the results become available quickly.
The COVID-19 pandemic has accelerated the growth of the global primary care POC diagnostics market. POCT provide the perfect tools for analysis of several viral diseases including COVID-19 virus and several hospital administrative bodies are making partnerships with scientists and researchers to take advantage of this fact. Many major hospitals are relying on a large amount of funding to start their research on the coronavirus through the POCT, thereby, fueling the growth of global primary care POC diagnostics market.
The report on the global primary care POC diagnostics market size includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes |
Details |
Report Title |
Primary Care POC Diagnostics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
Base Year |
2020 |
Historic Data |
2018–2019 |
Forecast Period |
2021–2028 |
Segmentation |
Products (Glucose Testing, Hb1Ac Testing, Coagulation, Fertility, Infectious Diseases, Cardiac Markers, Thyroid Stimulating Hormone, Hematology, Primary Care Systems, Decentralized Clinical Chemistry, Feces, Lipid Testing, Cancer Marker, Blood Gas/Electrolytes, Ambulatory Chemistry, Drug Abuse Testing, and Urinalysis) and End-users (Pharmacy & Retail Clinics, Physician Office, Urgent Care Clinics, and Non-practice Clinics) |
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Trends, and Revenue Forecast |
Key Players Covered in the Report |
Roche Diagnostics; BD Biosciences; Danaher Corporation; Abbott Laboratories; Instrumentation Laboratory; bioMerieux; Siemens Healthcare, and Quidel Corporation |
Glucose testing segment to hold a large revenue share
On the basis of products, the global primary care POC diagnostics market size is segmented into glucose testing, Hb1Ac testing, coagulation, fertility, infectious diseases, cardiac markers, thyroid stimulating hormone, hematology, primary care systems, decentralized clinical chemistry, feces, Lipid testing, cancer marker, blood gas/electrolytes, ambulatory chemistry, drug abuse testing, and urinalysis. The glucose testing segment is expected to hold a high revenue share of the market in the coming years owing to the high demand for glucose testing solutions due to rising cases of diabetes and growing number of the aging population globally.
On the other hand, the lipid testing segment is anticipated to constitute a large market share during the forecast period owing to wide commercial availability of lipid testing products worldwide. Moreover, the rise in research and development activities in this segment is another key driver for the rapid expansion of lipid testing products.
Physician office segment to dominate the market
Based on end-users, the market is divided into pharmacy & retail clinics, physician office, urgent care clinics, and non-practice clinics. The physician office segment is projected to dominate the market during the forecast period owing to the rising global demand for POCT devices from physicians. With the help of these devices, the patient care and workflow at the physician office has improved radically. The availability of POCT devices has been crucial factor in aiding complex tests with simple procedures and still being able to obtain accurate results. Therefore, factors such as stress-free, less time-consuming tests, and consumer demand for ease have boosted the growth of this segment.
The pharmacy & retail clinics segment, however, is expected to expand at a robust growth rate during the forecast period due to easy accessibility and cost-effective factors along with favorable insurance policies. Several insurance companies across the globe implement policies, having directly tied up to pharmacies and clinics, resulting to encourage the adoption of the diagnostics in pharmacy and retail clinics. Pharmacists have also started performing new tests such as glycosylated hemoglobin and cholesterol screening, which can be easily available for all.
North America held a major market share
In terms of regions, the market is classified as North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held a dominant market share in 2020 and the trend is projected to continue during the forecast period owing to primary reasons such as the wide availability of advanced healthcare infrastructure; technological superiority, and favorable reimbursement policies compared to other regions. The presence of key global players in this region, which offers services and products of both primary and secondary care settings can also become a major factor for the regional market growth.
On the other hand, the market in Asia Pacific is expected to grow at a fast pace during the forecast period owing to the growing awareness of the diagnostics and its benefits among health-conscious people as well as rising investment from both government authorities and private administrations to improve the testing process in the region.
The global primary care POC diagnostics market has been segmented in terms of
ProductsKey players competing in the global primary care POC diagnostics market are Roche Diagnostics; BD Biosciences; Danaher Corporation; Abbott Laboratories; Instrumentation Laboratory; bioMerieux; Siemens Healthcare, and Quidel Corporation. Most of these players are currently engaged in strategic initiatives including mergers & acquisitions, promoting awareness, and new product development to help them expanding their product portfolios and enhancing market positions. Roche Diagnostics introduced the Accutrend Plus system, which aimed to offer the complete and effective analysis of a patient who had undergone lipid testing in a short amount of time.